蛋白酶体抑制剂硼替佐米增强而非减轻感染鼠肝炎冠状病毒的小鼠的疾病。
The proteasome inhibitor Velcade enhances rather than reduces disease in mouse hepatitis coronavirus-infected mice.
机构信息
Virology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands.
出版信息
J Virol. 2010 Aug;84(15):7880-5. doi: 10.1128/JVI.00486-10. Epub 2010 May 19.
Abstract
Many viruses, including coronaviruses (CoVs), depend on a functional cellular proteasome for efficient infection in vitro. Hence, the proteasome inhibitor Velcade (bortezomib), a clinically approved anticancer drug, shown in an accompanying study (M. Raaben et al., J. Virol. 84:7869-7879, 2010) to strongly inhibit mouse hepatitis CoV (MHV) infection in cultured cells, seemed an attractive candidate for testing its antiviral properties in vivo. Surprisingly, however, the drug did not reduce replication of the virus in mice. Rather, inhibition of the proteasome caused enhanced infection with lethal outcome, calling for caution when using this type of drug during infection.
摘要
许多病毒，包括冠状病毒（CoV），在体外感染中依赖于功能性的细胞蛋白酶体。因此，蛋白酶体抑制剂硼替佐米（Velcade），一种已在临床中被批准的抗癌药物，在一项伴随研究中显示（M. Raaben 等人，J. Virol. 84:7869-7879, 2010）能强烈抑制细胞培养中的小鼠肝炎冠状病毒（MHV）感染，似乎是一种具有吸引力的候选药物，可在体内测试其抗病毒特性。然而，令人惊讶的是，该药物并没有降低病毒在小鼠体内的复制。相反，蛋白酶体的抑制导致感染增强并导致致命后果，因此在感染期间使用此类药物时需要谨慎。
相似文献
1
The proteasome inhibitor Velcade enhances rather than reduces disease in mouse hepatitis coronavirus-infected mice.
J Virol. 2010 Aug;84(15):7880-5. doi: 10.1128/JVI.00486-10. Epub 2010 May 19.
2
The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle.
J Virol. 2010 Aug;84(15):7869-79. doi: 10.1128/JVI.00485-10. Epub 2010 May 19.
3
Synergistic antiviral effect of a combination of mouse interferon-alpha and interferon-gamma on mouse hepatitis virus.
J Med Virol. 2003 Feb;69(2):188-94. doi: 10.1002/jmv.10286.
4
Bortezomib inhibits hepatitis B virus replication in transgenic mice.
Antimicrob Agents Chemother. 2010 Feb;54(2):749-56. doi: 10.1128/AAC.01101-09. Epub 2009 Nov 30.
5
Proteasome inhibition in vivo promotes survival in a lethal murine model of severe acute respiratory syndrome.
J Virol. 2010 Dec;84(23):12419-28. doi: 10.1128/JVI.01219-10. Epub 2010 Sep 22.
6
Treatment of human respiratory syncytial virus infected Balb/C mice with the proteasome inhibitor bortezomib (Velcade, PS-341) results in increased inflammation and mortality.
Toxicology. 2010 Jan 31;268(1-2):25-30. doi: 10.1016/j.tox.2009.11.014. Epub 2009 Nov 18.
7
Murine coronavirus ubiquitin-like domain is important for papain-like protease stability and viral pathogenesis.
J Virol. 2015 May;89(9):4907-17. doi: 10.1128/JVI.00338-15. Epub 2015 Feb 18.
8
"Development of the proteasome inhibitor Velcade (Bortezomib)" by Julian Adams, Ph.D., and Michael Kauffman, M.D., Ph.D.
Cancer Invest. 2004;22(2):328-9. doi: 10.1081/cnv-120030223.
9
Development of the proteasome inhibitor Velcade (Bortezomib).
Cancer Invest. 2004;22(2):304-11. doi: 10.1081/cnv-120030218.
10
The development of proteasome inhibitors as anticancer drugs.
Cancer Cell. 2004 May;5(5):417-21. doi: 10.1016/s1535-6108(04)00120-5.
引用本文的文献
1
Effects of immunoproteasome inhibition on acute respiratory infection with murine hepatitis virus strain 1.
J Virol. 2024 Dec 17;98(12):e0123824. doi: 10.1128/jvi.01238-24. Epub 2024 Nov 7.
2
Upregulated Proteasome Subunits in COVID-19 Patients: A Link with Hypoxemia, Lymphopenia and Inflammation.
Biomolecules. 2022 Mar 13;12(3):442. doi: 10.3390/biom12030442.
3
SARS-CoV-2 and other coronaviruses negatively influence mitochondrial quality control: beneficial effects of melatonin.
Pharmacol Ther. 2021 Aug;224:107825. doi: 10.1016/j.pharmthera.2021.107825. Epub 2021 Mar 1.
4
COVID-19 Usurps Host Regulatory Networks.
Front Pharmacol. 2020 Aug 14;11:1278. doi: 10.3389/fphar.2020.01278. eCollection 2020.
5
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.
Pharmacol Ther. 2020 Sep;213:107579. doi: 10.1016/j.pharmthera.2020.107579. Epub 2020 May 19.
6
Cellular Cullin RING Ubiquitin Ligases: Druggable Host Dependency Factors of Cytomegaloviruses.
Int J Mol Sci. 2019 Apr 2;20(7):1636. doi: 10.3390/ijms20071636.
7
Determination of host proteins composing the microenvironment of coronavirus replicase complexes by proximity-labeling.
Elife. 2019 Jan 11;8:e42037. doi: 10.7554/eLife.42037.
8
Ubiquitin-Proteasome System Is Required for Efficient Replication of Singapore Grouper Iridovirus.
Front Microbiol. 2018 Nov 26;9:2798. doi: 10.3389/fmicb.2018.02798. eCollection 2018.
9
Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond.
Nat Rev Drug Discov. 2017 Aug;16(8):565-586. doi: 10.1038/nrd.2017.33. Epub 2017 May 5.
10
Homologous recombination is a force in the evolution of canine distemper virus.
PLoS One. 2017 Apr 10;12(4):e0175416. doi: 10.1371/journal.pone.0175416. eCollection 2017.
本文引用的文献
1
The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle.
J Virol. 2010 Aug;84(15):7869-79. doi: 10.1128/JVI.00485-10. Epub 2010 May 19.
2
The proteasome inhibitor bortezomib enhances the susceptibility to viral infection.
J Immunol. 2009 Nov 15;183(10):6145-50. doi: 10.4049/jimmunol.0901596. Epub 2009 Oct 19.
3
Type I interferon receptor-independent and -dependent host transcriptional responses to mouse hepatitis coronavirus infection in vivo.
BMC Genomics. 2009 Aug 3;10:350. doi: 10.1186/1471-2164-10-350.
4
Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity.
Haematologica. 2009 Apr;94(4):470-8. doi: 10.3324/haematol.13783. Epub 2009 Feb 19.
5
Non-invasive imaging of mouse hepatitis coronavirus infection reveals determinants of viral replication and spread in vivo.
Cell Microbiol. 2009 May;11(5):825-41. doi: 10.1111/j.1462-5822.2009.01298.x. Epub 2009 Feb 10.
6
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.
Mol Cancer Ther. 2009 Feb;8(2):342-9. doi: 10.1158/1535-7163.MCT-08-0534. Epub 2009 Jan 27.
7
Inhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genes.
J Virol. 2009 Mar;83(6):2469-79. doi: 10.1128/JVI.01986-08. Epub 2009 Jan 7.
8
Orthopoxviruses require a functional ubiquitin-proteasome system for productive replication.
J Virol. 2009 Mar;83(5):2099-108. doi: 10.1128/JVI.01753-08. Epub 2008 Dec 24.
9
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
J Clin Oncol. 2008 Oct 10;26(29):4784-90. doi: 10.1200/JCO.2007.14.9641. Epub 2008 Aug 18.
10
Ubiquitination is required for effective replication of coxsackievirus B3.
PLoS One. 2008 Jul 9;3(7):e2585. doi: 10.1371/journal.pone.0002585.
Zotero 插件